Abstract:Triple-negative breast cancer (TNBC) is a highly aggressive, heterogeneous and invasive subtype of breast cancer with very limited effective modalities of treatment. Degrading the critical transcription regulator cyclin-dependent kinase 9 (CDK9) by proteolysis targeting chimeras (PROTACs) has shown promising potential for treating TNBC. However, to date, CDK9-targeting PROTACs for oral administration in treatment of cancers have not been reported. We herein present the design, synthesis, and extensive biological evaluation of a series of novel PROTACs as orally bioavailable, potent and selective degraders of CDK9 for targeting transcription regulation in triple-negative breast cancer. The developed compound 29 exhibited a desired potency (DC50 = 3.94 nM) with high efficacy (Dmax = 96 %) on CDK9 degradation, and effectively inhibited the proliferation of TNBC MDA-MB-231 cells. Mechanistic investigations revealed that compound 29 is a bona fide CDK9 degrader and can substantially downregulate the downstream targets c-Myc and MCL-1. Furthermore, compound 29 displayed favorable oral bioavailability in mice, and oral administration of degrader 29 significantly depleted CDK9 protein in TNBC tumor tissues and exhibited tumor growth inhibition in TNBC xenograft mice models. Collectively, our work established that degrader 29 is a highly potent and selective degraders of CDK9 with satisfactory oral bioavailability, which holds promising potential for the treatment of TNBC.

Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.

Design of Wogonin-Inspired Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitors with Potent in Vitro and in Vivo Antitumor Activity.

Discovery and Synthesis of Novel Wogonin Derivatives with Potent Antitumor Activity in Vitro.

Discovery of Selective CDK9 Degraders with Enhancing Antiproliferative Activity Through PROTAC Conversion

Discovery of Novel Flavonoid-Based CDK9 Degraders for Prostate Cancer Treatment Via a PROTAC Strategy.

Discovery of a Potent and Selective JAK1-targeting PROTAC Degrader with Anti-Tumor Activities

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

Novel Platinum(iv) Complexes Conjugated with a Wogonin Derivative As Multi-Targeted Anticancer Agents.

Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2h-pyran-4-carbonitrile (JSH-150) As a Novel Highly Selective and Potent CDK9 Kinase Inhibitor.

Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies

Wogonin Induced G1 Cell Cycle Arrest by Regulating Wnt/β-catenin Signaling Pathway and Inactivating CDK8 in Human Colorectal Cancer Carcinoma Cells

Identification of Novel Targets and Mechanisms of Wogonin on Lung Cancer, Bladder Cancer, and Colon Cancer

Discovery of the cereblon-recruiting tubulin PROTACs effective in overcoming Taxol resistance in vitro and in vivo

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

Discovery of 2H-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies

Development of Selective Mono or Dual PROTAC Degrader Probe of CDK Isoforms.

Potent and Preferential Degradation of CDK6 Via Proteolysis Targeting Chimera Degraders

Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer